Advantages of liposomal delivery systems for anthracyclines
- 1 December 2004
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 31, 5-15
- https://doi.org/10.1053/j.seminoncol.2004.08.001
Abstract
Liposomes, closed vesicular structures consisting of one or more lipid bilayers, have generated a great deal of interest as drug delivery vehicles. In particular, they have been investigated for their ability to improve the delivery of chemotherapeutic agents to tumors, in efforts to increase therapeutic efficacy and decrease toxicity to normal cells. Development of liposomal chemotherapeutic agents has, in the past, been hindered primarily by the rapid uptake of liposomes by the reticuloendothelial system. Numerous strategies that seek to either exploit or avoid this phenomenon have been used. As a result, several liposomal chemotherapeutic agents are now available in the clinic. STEALTH, a novel liposomal system coated with polyethylene glycol, avoids uptake by the reticuloendothelial system, thus improving drug delivery to the tumor while decreasing toxicity. In pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), this delivery system encapsulates doxorubicin within polyethylene glycol-coated liposomes, leading to promising new applications for a well-established drug. Liposome-encapsulated doxorubicin citrate complex (Myocet [NPLD]), another liposomal delivery system for doxorubicin, lacks the polyethylene glycol coating, resulting in much shorter circulation times than those of PLD. Daunorubicin citrate liposome (DaunoXome [DNX]) contains daunorubicin encapsulated in a smaller liposome of a different lipid composition. It has circulation times between those of PLD and NPLD. This article reviews the advantages of liposomal delivery systems in general and the divergent approaches that have been taken in developing these agents.Keywords
This publication has 66 references indexed in Scilit:
- Drug Delivery Systems: Entering the MainstreamScience, 2004
- The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicinAnnals Of Oncology, 1998
- Liposomal formulations of cytotoxic drugsSupportive Care in Cancer, 1996
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996
- Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplantsAntimicrobial Agents and Chemotherapy, 1995
- Ganglioside GM1and Hydrophilic Polymers Increase Liposome Circulation Times by Inhibiting the Association of Blood ProteinsJournal of Liposome Research, 1992
- Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.Proceedings of the National Academy of Sciences of the United States of America, 1991
- Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation timesBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991
- Pharmacokinetics of stealth versus conventional liposomes: effect of doseBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991
- Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscopeJournal of Molecular Biology, 1964